Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...

Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...

Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in a related lung disease leading the drugmaker to expand the indications it ...

The FDA has granted priority review to brensocatib to treat patients with non-cystic fibrosis bronchiectasis, according to a ...

Did you see this? Nearly 1 in 10 Americans have asthma. Here's what causes it.

One Conway woman is continuing to fight for her life after being diagnosed with Pulmonary Fibrosis in her battle with long ...

Comedy fans can catch Johnny Pizzi, Mark Riley, and Artie Januario at Giggles Comedy Club on Feb. 13 for a fundraiser ...

Insmed's promising drug pipeline includes Brensocatib and Arikayce. See why INSM stock is a strong pick with multi-billion ...

The FDA accepts and grants priority review to INSM's NDA for brensocatib to treat patients with non-cystic fibrosis bronchiectasis. A decision is due on Aug. 12, 2025.

Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers from the Technical University of Munich (TUM) have discovered that the ...

WILMORE, Ky. (WKYT) - A Wilmore woman made quite the discovery after receiving results from a DNA kit, one that would lead to ...